je.st
news
Tag: study
Execs in Asian luxury hotels fall prey to cyber espionage: study
2014-11-10 17:36:25| Wireless - Topix.net
Security researchers have uncovered a sophisticated industrial espionage campaign that targets business executives in luxury hotels across Asia once they sign on to computers using in-room wireless connections they consider private and secure. The attacks, which go well beyond typical cybercriminal operations, have claimed thousands of victims dating back to 2009 and continue to do so, Kaspersky Lab, the world's largest private security firm, shows in a report published on Monday.
Case Study: Subsea Oil & Gas Company
2014-11-10 16:37:00| Offshore Technology
Project details:
Case Study: Marine Dredging Company
2014-11-10 16:24:00| Offshore Technology
Project details:
Tags: company
case
study
marine
Interim Data from Proof-of-Concept Study of Merck's Investigational...
2014-11-10 08:38:26| Biotech - Topix.net
Merck , known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir , the company's investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide inhibitor for the treatment of chronic hepatitis C virus infection.
Tags: data
study
interim
investigational
Interim Data from Proof-of-Concept Study of Mercks Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting
2014-11-10 00:53:00| Merck.com - Research & Development News
Dateline City: BOSTON Merck Plans to Initiate Phase 2 C-CREST Program to Evaluate Mercks Triple Combination of Grazoprevir/Elbasvir with MK-3682 (formerly IDX21437), a Novel Nucleotide Inhibitor, in Q1 2015 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir (MK-5172/MK-8742, MK-5172A), the companys investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide (NS5B) inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orSarra Herzog, 201-669-6570orInvestor:Joe Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
data
study
presented
Sites : [582] [583] [584] [585] [586] [587] [588] [589] [590] [591] [592] [593] [594] [595] [596] [597] [598] [599] [600] [601] next »